---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Co-prescribed/Concomitant therapies. Topics: Darolutamide: class and labeled indications, Darolutamide: recommended dosage and concurrent androgen deprivation, Darolutamide: dosage modification for adverse reactions, Darolutamide: warnings and precautions, and 4 further topics. 8 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Darolutamide: class and labeled indications

> “NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with:”
> “non-metastatic castration-resistant prostate cancer (nmCRPC)”
> “metastatic castration-sensitive prostate cancer (mCSPC) in combination”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.12-2"></a>

### Darolutamide: recommended dosage and concurrent androgen deprivation

> “The recommended dose of NUBEQA is 600 mg orally, twice daily, with food”
> “Patients receiving NUBEQA should also receive a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or have had a bilateral orchiectomy.”
> “Advise patients to swallow tablets whole with food.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.12-3"></a>

### Darolutamide: dosage modification for adverse reactions

> “If a patient experiences a greater than or equal to Grade 3 or an intolerable adverse reaction, withhold NUBEQA or reduce dosage to 300 mg twice daily until symptoms improve.”
> “Dosage reduction below 300 mg twice daily is not recommended.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.12-4"></a>

### Darolutamide: warnings and precautions

> “Ischemic Heart Disease: Optimize management of cardiovascular risk factors. Monitor for signs and symptoms of coronary artery disease. Discontinue NUBEQA for Grade 3-4 events.”
> “Seizure: Consider discontinuation of NUBEQA in patients who develop a seizure during treatment.”
> “Embryo-Fetal Toxicity: NUBEQA can cause fetal harm and loss of pregnancy.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.12-5"></a>

### Darolutamide: dosage form and package

> “NUBEQA 300 mg tablets are available in bottles of 120 tablets.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.12-6"></a>

### Darolutamide: wholesale acquisition cost filing with the California Department of Health Care Access and Information

| Field | Quoted record |
| --- | --- |
| Manufacturer name | “Bayer” |
| National drug code | “50419039501” |
| Drug product description | “Nubeqa 300 mg tab 120 count” |
| WAC effective date | “2026-01-01T00:00:00” |
| WAC increase amount (USD) | “847.20” |
| WAC after increase (USD) | “15100.80” |

Source: [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27Nubeqa%25%27)

<a id="topic-2.1.2.12-7"></a>

### Darolutamide supply for Himalayas-1 under the Bayer agreement

> “Under the terms of the agreement, ORIC will conduct and sponsor the Himalayas-1 trial and Bayer will provide their AR inhibitor”
> “at no cost for use in the trial in combination with rinzimetostat. This agreement does not grant Bayer any license, option, or other rights to rinzimetostat and ORIC retains full global development and commercial rights to rinzimetostat.”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-2.1.2.12-8"></a>

### Continued androgen deprivation therapy in the rinzimetostat trials

> “Must have undergone bilateral orchiectomy or be willing to continue GnRH analogue or antagonist to maintain castrate levels of testosterone”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

> “Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
